QIAGEN N.V. confirmed strong Q1 2025 results on May 7, 2025, in line with its preliminary announcement, and reaffirmed its full-year 2025 outlook. The company reported net sales of $483.5 million, representing a 5.4% increase from Q1 2024, with adjusted diluted EPS of $0.55.
The Supervisory Board announced its intention to propose the initiation of an annual cash dividend of $0.25 per ordinary share, totaling approximately $54 million, for shareholder approval at the Annual General Meeting on June 26, 2025. The record date is planned for July 2, 2025, with payment on July 10, 2025.
Additionally, QIAGEN will seek shareholder approval for a new synthetic share repurchase authorization of up to $500 million. These capital allocation initiatives reflect QIAGEN’s strong financial position and its strategy to enhance shareholder returns while maintaining flexibility for organic investments and value-creating acquisitions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.